Fundraising FoxHelomics
AcquiredPittsburgh, US · Founded 2016 · 1 known investors
Find your way into Helomics
Sign up to find every way you can get introduced to Helomics
- Your email: who you already know at Helomics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Helomics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery. It serves pharmaceutical drug developers, offering drug-response predictions, drug repurposing, and pre-clinical tumor heterogeneity modeling.
Founders & leadership
GJ
GERALD J. VARDZEL JR.Executive
DA
DOUGLAS ARMSTRONGExecutive
Board
RD
ROBERT D. KEYSER JR.Board director
RA
RICHARD AULICINOBoard director
Investors · 1
Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.1M disclosed across 3 rounds · 2016–2017
▶$3MraisedApr 2018 · 48 investors · Other Health CareRule 506(b)
▶$3MraisedApr 2018 · 48 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- R. DOUGLAS ARMSTRONGExecutive Officer, Director
- GERALD J. VARDZEL JR.Executive Officer, Director
- ROBERT D. KEYSER JR.Director
- RICHARD AULICINODirector
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $35K
- Sales commissions
- $240K
- Placement agents
- DAWSON JAMES SECURITES, INC.
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$110KraisedJun 2017 · 5 investors · Other Health CareRule 506(b)
▶$110KraisedJun 2017 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- RICHARD AULICINODirector
- GERALD J. VARDZEL JR.Executive Officer, Director
- DOUGLAS ARMSTRONGExecutive Officer, Director
- ROBERT D. KEYSER JR.Director
- Offering amount
- $975K
- Amount sold
- $110K
- Sales commissions
- $78K
- Placement agents
- DAWSON JAMES SECURITES, INC.
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2MraisedMar 2017 · 33 investors · Other Health CareRule 506(b)
▶$2MraisedMar 2017 · 33 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT D. KEYSER JR.Director
- GERALD J. VARDZEL JR.Executive Officer, Director
- RICHARD AULICINODirector
- DOUGLAS ARMSTRONGExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2M
- Sales commissions
- $129.6K
- Placement agents
- DAWSON JAMES SECURITES, INC.
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Helomics do?
- Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery. It serves pharmaceutical drug developers, offering drug-response predictions, drug repurposing, and pre-clinical tumor heterogeneity modeling.
- Who are Helomics's investors?
- Helomics's investors include Longitude Capital.
- How much funding has Helomics raised?
- Helomics has disclosed $5.1M raised across 3 rounds.
- Where is Helomics headquartered?
- Helomics is headquartered in Pittsburgh, US.